mobile Health AG

Ricerca mobile Health

Qualità dei dati a livello accademico

In collaborazione con centri di ricerca sul cancro, cliniche e il settore delle scienze della vita, ci impegniamo per l’empowerment dei pazienti (partecipazione e codecisione in ambito sanitario) e per una raccolta di dati a livello di studi regolatori. I sintomi registrati dai pazienti, combinati con i dati clinici, aprono nuove conoscenze e opportunità per l’assistenza medica e la ricerca (real-world evidence).

Contattateci ora
Illustrazione: un medico esamina su un tablet i dati dell’andamento; accanto, uno schermo con grafici.

Dalle esperienze dei pazienti al progresso medico

Con medidux™ colleghiamo pazienti, professionisti sanitari e ricerca per trasformare preziosi dati sanitari in nuove conoscenze. Insieme creiamo le basi per un trattamento più mirato e personalizzato del cancro e delle malattie croniche.

In qualità di paziente

Sostiene la ricerca sui servizi sanitari condividendo i suoi dati nell’app in forma pseudonimizzata. In questo modo contribuisce a migliorare le cure con la sua esperienza di paziente, naturalmente su base volontaria.

In qualità di medico

Sostiene la ricerca sui servizi sanitari aiutando i suoi pazienti a utilizzare l’app e partecipando a studi e registri di eHealth.

Co-creazione

Avviare insieme nuovi approcci di ricerca: ha un’idea? Noi abbiamo gli strumenti, i contatti e l’esperienza necessari.

Contatto

Salute riferita dai pazienti

Rendere misurabile la prospettiva del paziente

ePROM, PROMIS e test adattivi spiegati in modo semplice

ePROMs

Strumenti di misura elettronici

I pazienti rispondono in formato digitale a questionari standardizzati sulla propria salute.

  • Sintomi
  • Funzionalità quotidiana
  • Qualità di vita

PROMIS

Un sistema di misura standardizzato

Questionari e banche di domande sviluppati scientificamente.

  • Funzione fisica
  • Fatigue
  • Interferenza del dolore

Questionari fissi o test adattivi

CAT

Le domande si adattano

Ogni risposta aiuta a scegliere la domanda successiva più adatta.

????

Fine del test secondo criteri prestabiliti

Come funziona un test adattivo

  1. Domanda
  2. Risposta
  3. Domanda successiva adatta
  4. Punteggio

ePROs = Electronic Patient-Reported Outcomes · ePROMs = Electronic Patient-Reported Outcome Measures · PROMIS = Patient-Reported Outcomes Measurement Information System · CAT = test adattivi computerizzati (Computerized Adaptive Testing)

Punteggi T PROMIS: media di riferimento 50 · deviazione standard 10 · valutazione per ambito

Rappresentazione schematica · nessuna domanda PROMIS originale

Publications: A Selection

  • Ongoing

    Efficiency of the "Medidux" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU) (EffiDux)

    This clinical trial evaluates whether using the medidux app for symptom and vital sign monitoring after discharge from Acute Admission Units can reduce short-term readmissions and emergency visits in non-urgent patients. By comparing outcomes between app users and those receiving standard care, the study aims to determine if digital follow-up improves post-discharge management and reduces unnecessary healthcare utilization.

  • Ongoing

    Swiss CanOn – Swiss Cannabis Oncology

    The Swiss CanOn registry uses the medidux platform to collect real-world data on the use of cannabis-based medicinal products in cancer care, combining physician-reported prescriptions with patient-reported outcomes via a smartphone app. This integrative approach aims to improve clinical understanding, support safer use, and inform future access to cannabinoid therapies.

  • JMIR Cancer, 202410.2196/54178

    Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

    Using the medidux app, patients treated with the HER2-targeted biosimilar Ogivri reported side effects and well-being outcomes equivalent to those of historical cohorts treated with Herceptin. Symptom burden was generally low and consistent across both groups. This real-world study shows that integrating an ePRO platform like medidux into care settings can reliably capture patient experiences, supporting informed treatment decisions and validating therapeutic equivalence in daily practice.

  • JMIR Cancer, 202110.2196/26950

    Effect of Collaborative Review of Electronic Patient-Reported Outcomes for Shared Reporting in Breast Cancer Patients: Descriptive Comparative Study

    This comparative study of two Consilium app versions showed that prompting structured patient-physician reviews significantly increased the number and quality of electronic symptom entries. Patients using the newer version reported more frequently and found the app more helpful during consultations. These insights directly informed the development of medidux, reinforcing that integrating shared digital monitoring into routine care can improve the accuracy of ePROs and foster more meaningful clinical dialogue.

  • Case Rep Oncol, 202010.1159/000507345

    Consilium Smartphone App for Real-World Electronically Captured Patient-Reported Outcome Monitoring in Cancer Patients Undergoing anti-PD-L1-Directed Treatment

    Six patients undergoing immunotherapy for advanced cancers used the Consilium app, medidux' predecessor, to log symptoms over three months, contributing over 1,200 real-time entries. Common symptoms like fatigue and shortness of breath were documented with detailed severity levels, triggering alerts without requiring unplanned visits. High satisfaction among patients and physicians highlighted how shared digital reporting via medidux can safely support outpatient care and improve the quality of clinical interactions.

  • A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical Trial

    In a randomized study of breast cancer patients undergoing chemotherapy, those who used Consilium (now medidux) to track symptoms and reviewed their data with a physician maintained stable daily functioning – unlike those without such review. Both groups using the app reported more adverse events than via traditional questionnaires provided only during planned visits, but supervised users made more precise, focused entries. These findings demonstrate medidux can support patient well-being and enhance symptom awareness during treatment.